Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge

V. A. Govan; N. D. Christensen; C. Berkower; W. R. Jacobs; A. L. Williamson

doi:10.1016/j.vaccine.2005.11.029

Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge

V. A. Govan
, N. D. Christensen
, C. Berkower
, W. R. Jacobs
, A. L. Williamson

Microbiology & Immunology

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Recombinant Bacille Calmette-Guerin (rBCG) could potentially be the vaccine vehicle of choice to deliver foreign antigens from multiple pathogens. In this study we have used the cottontail rabbit papillomavirus (CRPV) rabbit model to provide a "proof of concept" that immunisation with rBCG expressing the CRPV major capsid protein, L1 (rBCG/CRPVL1), will protect outbred New Zealand White rabbits against CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (10⁷ cfu/ml) were protected 5 weeks post-CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (10⁵ cfu/ml) had papillomas, which were smaller and took longer to appear than the control rabbits. None of the negative control rabbits vaccinated with rBCG expressing an irrelevant gene or PBS were protected from CRPV challenge. Sera from rabbits immunised with rBCG/CRPVL1 (10⁷ cfu/ml) were able to neutralise 54.5% of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine.

Original language	English (US)
Pages (from-to)	2087-2093
Number of pages	7
Journal	Vaccine
Volume	24
Issue number	12
DOIs	https://doi.org/10.1016/j.vaccine.2005.11.029
State	Published - Mar 15 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CRPV
Vaccine
rBCG

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2005.11.029

Cite this

@article{14d656ccbae9443eb7187ede331811da,

title = "Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge",

abstract = "Recombinant Bacille Calmette-Guerin (rBCG) could potentially be the vaccine vehicle of choice to deliver foreign antigens from multiple pathogens. In this study we have used the cottontail rabbit papillomavirus (CRPV) rabbit model to provide a {"}proof of concept{"} that immunisation with rBCG expressing the CRPV major capsid protein, L1 (rBCG/CRPVL1), will protect outbred New Zealand White rabbits against CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were protected 5 weeks post-CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (105 cfu/ml) had papillomas, which were smaller and took longer to appear than the control rabbits. None of the negative control rabbits vaccinated with rBCG expressing an irrelevant gene or PBS were protected from CRPV challenge. Sera from rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were able to neutralise 54.5\% of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine.",

keywords = "CRPV, Vaccine, rBCG",

author = "Govan, \{V. A.\} and Christensen, \{N. D.\} and C. Berkower and Jacobs, \{W. R.\} and Williamson, \{A. L.\}",

note = "Funding Information: We thank Marleze Rheeder for excellent animal handling, Jo-Anne Passmore for assisting with the statistical analysis and James Maclean, Maureen Dennehy and William Bourn for pioneering the BCG work in our laboratory. We also thank Robin Thomas for technical advice, Arvind Varsani, Eric van der Valt and Edward Rybicki for providing the VLPs. V.A. Govan was supported by the MRC, South Africa. This work was supported by grants NIH AI26170 to WRJ and the South African Department of Arts Culture, Science and Technology Innovation Funding and the Poliomyelitis Research Foundation to ALW.",

year = "2006",

month = mar,

day = "15",

doi = "10.1016/j.vaccine.2005.11.029",

language = "English (US)",

volume = "24",

pages = "2087--2093",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "12",

}

TY - JOUR

T1 - Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge

AU - Govan, V. A.

AU - Christensen, N. D.

AU - Berkower, C.

AU - Jacobs, W. R.

AU - Williamson, A. L.

N1 - Funding Information: We thank Marleze Rheeder for excellent animal handling, Jo-Anne Passmore for assisting with the statistical analysis and James Maclean, Maureen Dennehy and William Bourn for pioneering the BCG work in our laboratory. We also thank Robin Thomas for technical advice, Arvind Varsani, Eric van der Valt and Edward Rybicki for providing the VLPs. V.A. Govan was supported by the MRC, South Africa. This work was supported by grants NIH AI26170 to WRJ and the South African Department of Arts Culture, Science and Technology Innovation Funding and the Poliomyelitis Research Foundation to ALW.

PY - 2006/3/15

Y1 - 2006/3/15

N2 - Recombinant Bacille Calmette-Guerin (rBCG) could potentially be the vaccine vehicle of choice to deliver foreign antigens from multiple pathogens. In this study we have used the cottontail rabbit papillomavirus (CRPV) rabbit model to provide a "proof of concept" that immunisation with rBCG expressing the CRPV major capsid protein, L1 (rBCG/CRPVL1), will protect outbred New Zealand White rabbits against CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were protected 5 weeks post-CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (105 cfu/ml) had papillomas, which were smaller and took longer to appear than the control rabbits. None of the negative control rabbits vaccinated with rBCG expressing an irrelevant gene or PBS were protected from CRPV challenge. Sera from rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were able to neutralise 54.5% of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine.

AB - Recombinant Bacille Calmette-Guerin (rBCG) could potentially be the vaccine vehicle of choice to deliver foreign antigens from multiple pathogens. In this study we have used the cottontail rabbit papillomavirus (CRPV) rabbit model to provide a "proof of concept" that immunisation with rBCG expressing the CRPV major capsid protein, L1 (rBCG/CRPVL1), will protect outbred New Zealand White rabbits against CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were protected 5 weeks post-CRPV challenge. Rabbits immunised with rBCG/CRPVL1 (105 cfu/ml) had papillomas, which were smaller and took longer to appear than the control rabbits. None of the negative control rabbits vaccinated with rBCG expressing an irrelevant gene or PBS were protected from CRPV challenge. Sera from rabbits immunised with rBCG/CRPVL1 (107 cfu/ml) were able to neutralise 54.5% of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine.

KW - CRPV

KW - Vaccine

KW - rBCG

UR - https://www.scopus.com/pages/publications/32844462492

UR - https://www.scopus.com/pages/publications/32844462492#tab=citedBy

U2 - 10.1016/j.vaccine.2005.11.029

DO - 10.1016/j.vaccine.2005.11.029

M3 - Article

C2 - 16343704

AN - SCOPUS:32844462492

SN - 0264-410X

VL - 24

SP - 2087

EP - 2093

JO - Vaccine

JF - Vaccine

IS - 12

ER -

Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this